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the major challenges of liver transplantation for the patients with
hepatocellular carcinoma (HCC). Here, we aimed to explore the
role and mechanism of liver graft injury mobilizing regulatory T
cells (Tregs), which lead to late phase tumor recurrence after liver
transplantation.
Methods: The correlation among tumor recurrence, liver graft
injury and Tregs mobilization were studied in 257 liver trans-
plant recipients with HCC and orthotopic rat liver transplantation
models. The direct roles of CXCL10/CXCR3 signaling on Tregs
mobilization and tumor recurrence were investigated in
CXCL10/ and CXCR3/ mice models with hepatic IR injury.
Results: Clinically, patients received the graft with graft weight
ratio (GWR) <60% had higher HCC recurrence after liver trans-
plantation than the recipients with GWRP60% graft. More circu-
lating Tregs and higher intragraft TLR4/CXCL10/CXCR3 levels
were detected in recipients with GWR <60% graft. These results
were further validated in rat transplantation model. Foxp3+ cells
and expressions of TLR4, CXCL10, TGFb, CTLA-4 and CD274 were
increased in rat liver tumor tissues from small-for-size graft
group. In mouse model, the mobilization and recruitment of
Tregs were decreased in TLR4/, CXCL10/ and CXCR3/ mice
compared to wild-type mice. Moreover, less CXCR3+ Tregs wereJournal of Hepatology 20
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fluorescence intensity.recruited into liver in CXCL10 mice after hepatic IR injury.
The knockout of CXCL10 and depletion of Tregs inhibited tumor
recurrence after hepatic IR injury.
Conclusion: CXCL10/CXCR3 signaling upregulated at liver graft
injury directly induced the mobilization and intragraft recruit-
ment of Tregs, which further promoted HCC recurrence after
transplantation.
Lay summary: There were positive correlation among tumor
recurrence, circulating Tregs and liver graft injury after human
transplantation for HCC patients. The knockout of CXCL10
decreased hepatic recruitment of CXCR3+ Tregs and late phase
tumor recurrence after hepatic IR injury.
 2016 European Association for the Study of the Liver. Published
by Elsevier B.V. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Hepatocellular carcinoma (HCC) is the fifth most frequent malig-
nancy in the world and the second cause of cancer-related mor-
tality [1]. Liver transplantation is an effective therapeutic
modality for the treatment of HCC patients and offers higher long
term survival prospects compared to liver resection and local
ablation [2]. Living donor liver transplantation (LDLT) has been
developed as an alternative choice to overcome the critical short-
age of liver grafts from deceased donors, and to shorten the wait-
ing time and decrease waitlist mortality [2]. With the
accumulation of liver transplantation for HCC patients, liver
tumor recurrence after transplantation has become an important
issue affecting the outcomes of liver transplantation [3]. The cur-
rent opinions regarding the difference in HCC recurrence
between LDLT and deceased donor liver transplant (DDLT)
remains controversial [4,5]. Several liver transplantation centers
have reported that the tumor recurrence after LDLT is higher
compared to DDLT [6–8]. The liver graft from living donor is usu-
ally small-for-size for the recipient, and is associated with a16 vol. 65 j 944–952
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higher incidence of acute-phase liver graft injury [9]. Several
studies have demonstrated that liver graft injury promoted
tumor cell adhesion, invasion, and angiogenesis [10–12].
However, the mechanism of liver graft injury promoting late
phase tumor recurrence after transplantation has not been well
defined.
Liver graft injury is typified as an amplified and deleterious
inflammatory response [13]. A multitude of different cytokines
and chemokines as well as immune cells are involved in these
inflammatory process. Toll-like receptor 4 (TLR4) has been
demonstrated to initiate the inflammatory response in hepatic
ischemia reperfusion (IR) injury via the activation of IRF3 medi-
ated MyD88-independent signal pathway [14,15]. C-X-C motif
chemokine 10 (CXCL10), a downstream product of TLR4-IRF3 sig-
naling, was also proven to be responsible for inflammatory
response during hepatic IR injury [16]. Recent research showed
that CXCL10 signaling contributes to melanoma growth and
metastasis through regulation of cellular adhesion, invasion and
migration properties [17]. Our previous paper also demonstrated
that CXCL10 was overexpressed in small-for-size liver graft and
promoted HCC invasiveness via regulating endothelial progenitor
cells and macrophages [12,18]. Furthermore, CXCL10 can recruit
more regulatory T cells (Tregs) trafficking to the liver through
their surface receptor CXCR3 [19,20]. However, the role and
mechanism of CXCL10/CXCR3 signaling in regulating Tregs mobi-
lization and late phase tumor recurrence after liver transplanta-
tion are unclear.
Tregs, were first proposed in 1970 as the term for suppressor T
cells, which play important roles in maintaining immune toler-
ance and controlling inflammatory diseases [21,22]. Tregs exert
their suppressive effects either via cell contact dependent man-
ner by membrane-bound molecules or through contact indepen-
dent manner mainly by release of inhibitory cytokines [23]. Tregs
can ligate CD80/CD86 on effector T cells and DCs through CTLA-4,
and result in suppression of effector T cells function and T cells
deletion [24]. Secretion of inhibitory cytokines such as transform-
ing growth factor (TGF)-b and interleukin (IL)-10 can inhibit T
cells proliferation and differentiation as well as suppress macro-
phages activation and dendritic cell (DC) maturation [25,26]. In
addition, the programmed death-1 receptor (CD279 or PD-1)
and its ligand (CD274 or PD-L1) also play important roles in pro-
moting Tregs development and enhancing Tregs function [27,28].
Recently, Tregs are considered to play critical roles in the induc-
tion of transplant tolerance and prevent allograft rejection. Adop-
tive transfer of Tregs can regulate the rejection response of naïve
T cells, prevent allograft rejection and prolong graft survival
[29,30]. This negative regulatory activity, however, can also sup-
press the immune responses against tumors and thereby pro-
mote tumor growth and progress. In the cancer patients, Tregs
are significantly mobilized to the peripheral blood and accumu-
late in tumor regions [31,32]. Furthermore, the high correlation
between frequency of Tregs in cancer patients and their mortality
were found in different cancers [32,33]. The Tregs isolated from
the tumor have potent immunosuppressive activity against effec-
tor immune cell response and thereby help tumor escape from
the host immunosurveillance [34]. However, the effect and mech-
anism of Tregs in tumor recurrence after transplantation is still
unknown. Therefore, strategies aimed to deplete Tregs or to func-
tionally inactivate Tregs is an interesting approach for increasing
anti-cancer immunity thereby suppressing tumor growth and
recurrence.Journal of Hepatology 201In this project, we aimed to study the role and mechanism of
acute-phase liver graft injury mobilizing Tregs, which lead to late
phase tumor recurrence after liver transplantation. The
correlation among liver graft injury, inflammatory cytokines/
chemokines, Tregs mobilization, and tumor recurrence were
investigated in both human and rat liver transplantation. The
direct roles of CXCL10/CXCR3 signaling on mobilization and
recruitment of Tregs together with tumor recurrence were fur-
ther explored in CXCL10/ and CXCR3/ mice model with hep-
atic IR injury.Materials and methods
Patients and specimens
From 1995 to 2013, 257 patients with HCC received liver transplantation in
Department of Surgery, Queen Mary Hospital, The University of Hong Kong, were
included in current study. The graft weight ratio (GWR) is the liver graft weight
divided by the estimated standard liver weight of the recipient [9]. According
to GWR above or below 60%, they were categorized into GWRP60% group (large
liver graft, n = 107) and GWR <60% group (small-for-size liver graft, n = 150). The
human liver graft biopsy samples were collected at 2 h after portal vein reperfu-
sion and blood samples were collected at day 0, day 7, 1 month, 3 months,
6 months and 12 months after transplantation. The study protocol was approved
by the Institutional Review Board of the University of Hong Kong (IRB approval
number: UW_11-099). Informed consent was obtained from each patient.
Animal models
Rats and C57BL/6 mice were purchased from the Laboratory Animal Unit, The
University of Hong Kong (HKULAU). The TLR4, CXCL10, and CXCR3 knockout mice
were described in previous paper [12,35]. The study had been licensed according
to Animal Ordinance Chapter 340 by the Department of Health, Hong Kong Spe-
cial Administrative Region (ref.: (14–613) in DH/HA&P/8/2/3 Pt. 63).
Rat orthotopic liver transplantation models
Orthotopic rat liver transplantation model using whole graft or small-for-size
graft (about 50%) was established [36]. Blood and liver samples were collected
at day 1, 3 and 5 respectively after liver transplantation to analyze Tregs mobi-
lization and intragraft recruitment. To detect Tregs and expressions of inflamma-
tory cytokines/chemokines in recurrent tumors, a rat liver transplantation model
with tumor recurrence was also used as described in our previously paper [10].
Liver graft samples and liver tumor tissues were collected at day 14 after liver
transplantation for further analyses.
Mouse model with major hepatectomy and hepatic IR injury
TLR4, CXCL10 and CXCR3 knockout mice and wild-type mice were subjected to
major hepatectomy (left and caudate lobes) and partial hepatic IR injury
(45 min ischemia of right and triangle lobes), which mimics transplantation with
small-for-size liver grafts [37]. Blood and liver samples were collected at day 1, 3
and 5 after reperfusion to analyze Tregs mobilization and intragraft recruitment.
In order to explore the effect of CXCL10 and Tregs on tumor recurrence,
mouse HCC cells (Hepa1-6, 1  106/in 100 ll) were injected through portal vein
after reperfusion in CXCL10/ mouse, to mimic the clinical scenario of circulating
tumor cells homing to the graft after liver transplantation. In the group of Tregs
depletion, the anti-mouse CD25 antibody (250 lg) was injected into peritoneal at
day 1 before operation, and day 5 after hepatic IR injury in wild-type mouse,
respectively. Liver tumor tissues were collected at day 14 after the operation.
Detection of circulating Tregs by flow cytometry
The numbers of circulating and hepatic Tregs were detected by flow cytometry.
The details of flow cytometry were described in our previous paper [38]. Cells
were stained with PE-Cy5-conjugated anti-CD4 (eBioscience, San Diego, CA)
and PE-conjugated anti-CD25 (BD Pharmingen, San Diego, CA), and then perme-
abilized with fixation/permeabilization working solution and incubated with
FITC-conjugated anti-Foxp3 (eBioscience, San Diego, CA). The matched isotype
controls were also prepared at the same time. Furthermore, the expressions of6 vol. 65 j 944–952 945
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CTLA-4, CD274, CD279, and CXCR3 in CD4+ CD25+ Tregs were also detected by
flow cytometry. The expression levels of CTLA-4, CD274, and CD279 in liver Tregs
were expressed by mean fluorescence intensity (MFI).
Isolation of spleen CD4+ CD25+ Tregs
The spleen CD4+ CD25+ Tregs were purified from C57BL/6 and CXCL10/ mice
using a CD4+ CD25+ Tregs isolation kit (Miltenyi Biotec, GmbH, Germany), accord-
ing to the manufacturer’s recommendation. The CD4+ CD25+ Tregs were cultured
in Roswell Park Memorial Institute (RPMI) 1640 medium with anti-CD3 (2.5 lg/
ml), anti-CD28 (2.5 lg/ml) and IL-2 (500 U/ml). 3 days later, the expressions of
CTLA-4, CD274 and CD279 in spleen Tregs were detected by flow cytometry.
Detection of gene expression by real-time RT-PCR
RT-PCR was done with a modified version of a previous method. Gene expression
levels were expressed as the folds relative to the normal liver [37].
Statistical analysis
The Chi-square test was carried out for the analysis of clinical correlation among
graft size clinical features and tumor recurrence after liver transplantation. The cor-
relation among the intragraft expressions of TLR4, CXCL10, CXCR3 and Tregs were
analyzed by Spearman correlation. All the comparisons for the study in animals
were performed using Student t test. p <0.05 was considered statistically signifi-
cant. Calculationswere performed by using the SPSS computer software version 16.Results
The tumor recurrence rate was higher in HCC recipients with small-
for-size liver graft
From 1995 to 2013, 257 patients with HCC received liver trans-
plantation in our liver transplantation center. HCC recurrence
occurred in 39 recipients after liver transplantation. The clinical
parameters related to tumor recurrence were summarized in
Table 1. Among these characteristics, the recurrence of HCC
was more frequent in the patients with advanced TNM stage
(p = 0.003), beyond Milan and University of California San Fran-
cisco (UCSF) criteria (p = 0.007 and p = 0.000 respectively),
venous infiltration (p = 0.000), higher serum alphafetoprotein
(AFP) (p = 0.001) and positive HBsAg (p = 0.027). In addition,
tumor recurrence was also related to GWR (p = 0.028) (Table 1).
According to GWR, the HCC recipients were categorized into
GWR P60% group (large liver graft, n = 107) and GWR <60%
group (small-for-size liver graft, n = 150). The comparison of
the clinical-pathological characteristics between the HCC recipi-
ents in GWR P60% and GWR <60% group were listed in Table 2.
Significant higher cumulative recurrence (29/150 (19.3%) vs.
10/107 (9.3%), p = 0.028) was found in the HCC recipients with
small-for-size liver graft after transplantation (Table 2). The per-
centage of patients with advanced TNM stage, high AFP levels,
and beyond Criteria of Milan or UCSF were similar between
GWRP60% and GWR <60% groups (Table 2). However, the recip-
ients in small-for-size liver graft group had higher venous infil-
tration (24/102 vs. 57/149, p = 0.014) and less hepatitis B Virus
(HBV) positive patients (95/107 vs. 117/150, p = 0.025) (Table 2).
The circulating Tregs were higher in the recipients with small-for-
size liver graft and HCC recurrence after human transplantation
Tregs can suppress the immune responses against tumors and
thereby promote tumor growth. In order to investigate the946 Journal of Hepatology 201mechanism of HCC recurrence after liver transplantation, we ana-
lyzed the mobilization of Tregs at different time points after
human liver transplantation. Before transplantation, there was
no difference of circulating Tregs between the recipients with
large liver graft and small-for-size liver graft. The patients
received small-for-size liver graft had more circulating Tregs at
day 7, 1 months and 3 months after transplantation than those
with large liver graft (Fig. 1A). Furthermore, more circulating
Tregs were also found in patients with HCC recurrence at
1 month, 3 months and 6 months after transplantation than
those without HCC recurrence (Fig. 1B).
Intragraft expressions of inflammatory cytokines/chemokines were
increased in the recipients with small-for-size liver graft and HCC
recurrence after human transplantation
In order to further explore the mechanism of Treg mobilization
after liver transplantation, we compared the expressions of
cytokines/chemokines between two groups. Our results indicated
that there were significantly higher intragraft TLR4, CXCL10 and
CXCR3 expression levels at 2 h after reperfusion in small-for-
size liver graft compared with large liver graft (Fig. 2A). The
expression of CD274 was also upregulated in the small-for-size
liver graft (Supplementary Fig. 1A). Furthermore, the intragraft
expressions of TLR4, CXCL10 and CXCR3 were also significantly
higher in the recipients with HCC recurrence compared to those
without HCC recurrence (Fig. 2B). There were positive correla-
tions among the intragraft expressions of TLR4, CXCL10, CXCR3
and CD274 after transplantation (Supplementary Figs. 1C and
2). Importantly, there were positive correlation among the circu-
lating Tregs and the intragraft expressions of TLR4, CXCL10, and
CXCR3 after human transplantation (Fig. 2C).
Association among inflammatory cytokines/chemokines expressions,
Tregs recruitment and tumor recurrence in rat orthotopic liver
transplantation (OLT) models
We further compared the circulating mobilization and hepatic
recruitment of Tregs between whole liver graft and small-for-
size liver graft in rat OLT models. The recipient rats with
small-for-size liver graft possessed approximately 2-fold increase
of circulating Tregs at day 5 after transplantation vs. whole liver
graft (Fig. 3A). Consistently, the number of Tregs recruited to
small-for-size liver graft was higher than that in whole liver graft
(Day 1: 268 cells vs. 139 cells/per 105 cells, p = 0.04; Day 5:
1019 cells vs. 480 cells/ per 105 cells, p = 0.02) (Fig. 3B). Further-
more, compared to whole liver graft group, intragraft mRNA
expression level of TLR4 was significantly elevated in small-for-
size liver graft on day 3 and 5 after rat transplantation (Supple-
mentary Fig. 3A). Our previous study also reported that the
expressions of CXCL10 and CXCR3 were significantly elevated in
small-for-size liver graft after rat transplantation [12].
We already reported greater tumor burden in small-for-size
liver graft at day 14 after transplantation compared with whole
liver graft in a rat OLT model with tumor recurrence [10]. In cur-
rent study, we also found that there were more Foxp3 positive
cells (8.7 cells vs. 4.7 cells/HPF, p = 0.004) in tumors developed
in small-for-size liver graft (Fig. 3C). After recruitment and hom-
ing of Tregs to the tissue, Tregs exerted their suppressive effects
either via cell contact dependent manner by membrane-bound
molecules or through contact independent manner mainly by6 vol. 65 j 944–952
Table 2. Clinico-pathological Characteristics of recipients with GWR P60%
and GWR <60% group.
Clinico-pathological    
features
Number GWR ≥60% 
N = 107
GWR <60% 
N = 150
p value
Sex 0.611
   Male 215 91 124
   Female 42 16 26
Age 0.256
   ≥55 years 143 64 79
   <55 years 114 43 71
TNM stagea 0.802
   Early stage (I-II) 101 42 59
Advanced stage (III-IV) 150 60 90
Milan criteriaa 0.868
   Within criteria 164 67 97
   Beyond criteria 88 35 53
UCSFa 0.926
   Within criteria 191 77 114
   Beyond criteria 61 25 36
Venous infiltrationa 0.014*
   Absent 170 78 92
   Present 81 24 57
HBsAg 0.025*
   Negative 45 12 33
   Positive 212 95 117
AFP level 0.071
   ≥20 ng/ml 130 47 83
   <20 ng/ml 127 60 67
One year recurrence 0.083
   Recurrence 18 4 14
   Non-recurrence 239 103 136
Cumulative recurrence 0.028*
   Recurrence 39 10 29
   Non-recurrence 218 97 121
aTotal number less than 257 due to missing data; ⁄p <0.05.
Table 1. Analyses of risk factors for HCC recurrence after liver transplantation.
Number Recurrence 
N = 39
Non-recurrence 
N = 218
p value
Sex 0.264
   Male 215 35 180
   Female 42 4 38
Age 0.019*
   ≥55 years 143 15 128
   <55 years 114 24 90
TNM stagea 0.003*
   Early stage (I-II) 101 7 94
   Advanced stage
   (III-IV)
150 31 119
Milan criteriaa 0.007*
   Within criteria 164 18 146
   Beyond criteria 88 21 67
UCSFa 0.000*
   Within criteria 191 19 172
   Beyond criteria 61 20 41
Venous infiltrationa 0.000*
   Absent 170 15 155
   Present 81 23 58
HBsAg 0.027*
   Negative 45 2 43
   Positive 212 37 175
AFP level 0.001*
   ≥20 ng/ml 130 29 101
   <20 ng/ml 127 10 117
GWR 0.028*
   ≥60% 107 10 97
   <60% 150 29 121
aTotal number less than 257 due to missing data; ⁄p <0.05.
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sues, the expressions of TLR4, CXCL10, CD274 and IL-10 were
higher in small-for-size liver graft than those in whole liver graft
(Fig. 3D and Supplementary Fig. 3B). Consistently, the expres-
sions of TGF-b and CTLA-4 were also increased in tumor tissues
from small-for-size liver graft (Supplementary Fig. 3B). Further-
more, the expressions of TGF-b, CTLA-4, CXCL10, CXCR3, CD274
and CD279 were upregulated in tumor tissues compared to
non-tumor tissues (Fig. 3D and Supplementary Fig. 3B).
The knockout of CXCL10/CXCR3 signaling reduced the mobilization
and recruitment of Tregs
Both the clinical and animal studies showed the correlations
among CXCL10/CXCR3 signaling, Tregs mobilization and tumor
recurrence after liver transplantation. We then proceeded to
investigate the direct role of CXCL10/CXCR3 signaling on Tregs
mobilization and recruitment in mouse hepatic IR injury model
using TLR4/, CXCL10/ and CXCR3/ mice. A significant
decrease of Tregs mobilization in circulation was observed in
TLR4/ mice compared to wild-type mice after hepatic IR injury
(Day 3: 940 cells vs. 510 cells/per105 PBMC, p = 0.04; Day 5: 1134
cells vs. 541 cells/per105 PBMC, p = 0.02) (Fig. 4A). In order to fur-
ther determine whether the mobilization and recruitment of
Tregs after liver injury was dependent on the CXCL10/CXCR3 sig-
naling, CXCL10/ mice and CXCR3/ mice hepatic IR injury
model were applied. The circulating and hepatic Tregs wereJournal of Hepatology 201decreased both in CXCL10/ and CXCR3/ mice after hepatic
IR injury (Fig. 4B and C). Before hepatic IR injury, there was no
difference of circulating and hepatic Tregs among these knockout
mice and wild-type mice.
Furthermore, we also investigated the expressions of TLR4,
CXCL10 and CXCR3 in mouse liver after hepatic IR injury and
major hepatectomy. The expressions of TLR4, CXCL10 and CXCR3
were significantly elevated in small liver remnant from wild-type
mice at day 1, 3 and 5 after hepatic IR injury and liver resection
(Supplementary Fig. 4A–C). The knockout of TLR4 decreased the
hepatic expressions of CXCL10 and CXCR3. The expressions of
TLR4 and CXCR3 were also downregulated in the small liver rem-
nant of CXCL10/ mice after hepatic IR injury and major hepate-
ctomy (Supplementary Fig. 4A–C). Furthermore, the expressions
of CD274, CTLA-4 and IL-10 were reduced in TLR4/, CXCL10/
and CXCR3/ mice compared to wild-type mice (Supplementary
Fig. 4D–F). However, there was no significance in TGF-b expres-
sion among these knockout and wild-type mice.
The knockout of CXCL10 decreased hepatic recruitment of CXCR3+
Tregs after hepatic IR injury
Since CXCL10 recruits cells via its cognate receptor CXCR3, the
cells recruited must express CXCR3. Therefore, we next6 vol. 65 j 944–952 947
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determined whether CXCR3+ Tregs were recruited into the liver
after hepatic IR injury. Before hepatic IR injury, there was similar
CXCR3+ Tregs in liver between CXCL10/ mice and wild-type
mice. The knockout of CXCL10 resulted in a significant decrease
in the number of hepatic CXCR3+ Tregs compared with wild-
type mice (Day 1: 226 cells vs. 64 cells/per105 NPCs, p = 0.03;
Day 3: 152 cells vs. 35 cells/per105 NPCs, p = 0.01; Day 5: 324
cells vs. 50 cells/per105 NPCs, p = 0.00) (Fig. 5A). On the contrary,
the number of circulating CXCR3+ Tregs was higher in CXCL10/
mice at day 1 and day 3 after hepatic IR injury compared with
wild-type mice (Fig. 5B). It indicated that knockout of CXCL10 sig-
nificantly suppressed hepatic recruitment of CXCR3+ Tregs.
The knockout of CXCL10 did not change the expressions of CTLA-4,
CD274 and CD279 on Tregs
The association and functional study showed that CXCL10/CXCR3
signaling may contribute to Tregs mobilization and recruitment
after liver transplantation. We further investigated the role of
CXCL10/CXCR3 signaling on Tregs function both in vivo and
in vitro. CTLA-4, CD274 and CD279 expressed in Tregs and play
important roles in maintaining and enhancing Tregs function.
Firstly, we detected the expressions of CD274, CD279 and
CTLA-4 in Tregs recruited to liver after hepatic IR injury. The
expression levels of CD274, CD279 and CTLA-4 in liver Tregs after
hepatic IR injury were similar in CXCL10/ mice and wild-type
mice (Fig. 5C–E). Furthermore, we also examined the role of
CXCL10 signaling on the function of the primary spleen Tregs
from CXCL10/ and wild-type mice. There were comparable per-
centages of CD274+, CD279+ and CTLA-4+ spleen Tregs between
CXCL10/ group and wild-type group (Supplementary Fig. 5).
The knockout of CXCL10 and depletion of Tregs inhibited tumor
recurrence after hepatic IR injury
In order to further explore the effects of CXCL10 and Tregs on late
phase tumor recurrence, mouse hepatic IR injury model with
tumor development was applied. Compared to wild-type mice,
the knockout of CXCL10 was significantly inhibited tumorA B
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Fig. 1. The circulating Tregs were higher in patients with small-for-size liver
graft and HCC recurrence after human transplantation. The circulating Tregs
were detected at day 0, day 7, 1 month, 3 months, 6 months, and 12 months by
flow cytometry. (A) The patients received small-for-size liver graft (GWR <60%)
had more circulating Tregs at day 7, 1 months and 3 months after transplantation
than patients with large liver graft (GWRP60%). (B) More circulating Tregs were
found in patients with HCC recurrence at 1 month, 3 months and 6 months after
transplantation than patients without HCC recurrence. (⁄p <0.05.)
948 Journal of Hepatology 201development after hepatic IR injury (Fig. 6AandB). At 14 days after
hepatic IR injury, hepatic replacement area by tumor was about
60.3% in wild-type mice when compared with 39.6% in CXCL10/
mice. Furthermore, we also examined the effect of Tregs depletion
on tumor development after hepatic IR injury. The depletion of
Tregs by CD25 monoclonal antibody treatment was confirmed
(Supplementary Fig. 6). The depletion of Tregs significantly inhib-
ited tumor development after hepatic IR injury (Fig. 6A and B).Discussion
Although liver transplantation is an effective therapeutic modal-
ity for the treatment of HCC patients, HCC recurrence after liver
transplantation remains a critical issue [2]. The rate of HCC recur-
rence was significantly higher following LDLT compared to DDLT
[7,8]. However, the precise mechanisms of tumor recurrence after
liver transplantation haven’t been clearly explored. Therefore, it
is worthwhile to reveal the molecular mechanism of tumor recur-
rence after transplantation and to identify the potential thera-
peutic target for new treatment.
In this study, we explored for the first time the potential
mechanism of Tregs in bridging liver graft injury and tumor
recurrence after liver transplantation. In clinical cohort, 15.2%
of the HCC recipients occurred tumor recurrence after liver trans-
plantation. The recurrence of HCC was associated with advanced
TNM stage, beyond Milan and UCSF criteria, venous infiltration,
higher serum AFP and positive HBsAg. In addition, tumor recur-
rence was also related to GWR. The patients received small-for-
size liver graft had significantly higher HCC recurrence incidence
than those with large liver graft after transplantation. Our clinical
outcome was similar to those with higher recurrence rates fol-
lowing LDLT compared to DDLT from other transplantation cen-
ters [7,8]. Importantly, similar proportion of the recipients with
advanced TNM stage, high AFP levels, and beyond Criteria of
Milan and UCSF was found between small-for-size graft and large
graft. It suggested that small-for-size liver graft itself might be an
independent risk factor and contribute to tumor recurrence after
liver transplantation.
It has been reported that Tregs play important roles in tumor
immunity [33]. There are more Tregs both in circulation and
tumor tissues of the patients bearing tumor [39,40]. Tregs help
tumor cells to escape from the host immunosurveillance by their
potent immunosuppressive activity against effector immune cell
response. Depletion and inhibition of Tregs promote develop-
ment of tumor immunity and inhibit tumor growth [41,42]. In
our clinical study, more circulating Tregs were found in the
patients implanted with small-for-size liver graft and those
developed HCC recurrences after transplantation. Consistently,
there were more circulating and hepatic Tregs in small-for-size
liver graft after rat transplantation. Furthermore, Foxp3 positive
cells and expressions of TGF-b, CTLA-4 and CD274 were also
increased in the tumor tissues from small-for-size graft group
compared to whole graft group. In mouse model, the knockout
of CXLC10 also decreased the hepatic expressions of IL-10,
CTLA-4, and CD274. Furthermore, the knockout of CXCL10 and
depletion of Tregs inhibited tumor recurrence after hepatic IR
injury. Tregs can secret inhibitory cytokines such as TGF-b and
IL-10, which can inhibit T-cell proliferation and differentiation
as well as suppress macrophage activation and DC maturation
[26,33]. CTLA-4-expressing Tregs can suppress effectors T cells6 vol. 65 j 944–952
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Fig. 5. The knockout of CXCL10 decreased the hepatic recruitment of CXCR3+
Tregs after hepatic IR injury. (A) The knockout of CXCL10 resulted in a significant
decrease in the number of hepatic CXCR3+ Tregs compared to wild-type (WT). (B)
The number of circulating CXCR3+ Tregs was higher in CXCL10/ mice at day 1
and day 3 after hepatic IR injury compared to WT mice. (C) The expression levels
of CTLA-4, CD274 and CD279 in liver Tregs after liver IR injury were similar
between CXCL10/ mice and WT mice. (N = 3–5/group; ⁄p <0.05.)
Research Articleby ligating CD80, resulting in the inhibition of T-cell proliferation
and cytokine production [43]. In addition, both CD274 and CD279
expressed in Tregs and play important roles in promoting Tregs
development and enhancing Tregs function [27]. These results
indicated that the mobilization of Tregs by small-for-size graft
injury may contribute to HCC recurrence after liver transplanta-
tion. The effects of CTLA-4, CD279 and its ligands on Tregs func-
tion and their inhibition of anti-tumor immunity need to further
studies.
The liver graft from a living donor is usually small-for-size for
the recipient, and is associated with a higher incidence of acute-
phase graft injury [9]. Several studies have demonstrated that
small-for-size liver graft injury has serious inflammatory
response and higher expressions of inflammatory cytokines/
chemokines [9,16]. In this study, we found that the expressions
of TLR4, CXCL10 and CXCR3 were significantly increased in
small-for-size liver graft after transplantation both in human
and rat. Importantly, the expressions of TLR4, CXCL10 and CXCR3
were correlated with the frequency of circulating Tregs. Recently
research showed that CXCL10 can recruit more Tregs trafficking
to the liver through their surface receptor CXCR3 after natural
killer (NK) cells activation [19]. CXCR3 is expressed on Tregs
and mediates Tregs mobilization [20,44]. However, the effect of
CXCL10/CXCR3 in regulating Tregs mobilization and recruitment
after liver transplantation has not been clearly explored. We
investigated for the first time the direct roles of TLR4, CXCL10
and CXCR3 on mobilization and recruitment of Tregs using950 Journal of Hepatology 201TLR4/, CXCL10/ and CXCR3/ mice underwent hepatic IR
injury and major hepatectomy. Significant less circulating mobi-
lization and hepatic recruitment of Tregs were found in TLR4/,
CXCL10/ and CXCR3/ mice. Our results also showed that the
number of CXCR3+ Tregs recruitment into the liver was decreased
in CXCL10/ mice after hepatic IR injury. These results indicated
that liver graft injury upregulated intragraft expressions of TLR4
and CXCL10, which further recruited the CXCR3+ Tregs into the
liver. We also investigated the effect of CXCL10 signaling in the
function of Tregs through in vitro and in vivo experiment. Our
results showed that the expression levels of CD274, CD279 and
CTLA-4 were similar in liver Tregs after hepatic IR injury and pri-
mary Tregs from spleen between CXCL10/ group and wild-type
group. These results suggested that CXCL10 may only contribute
to Tregs mobilization and recruitment but do not change Tregs
function. Several studies have demonstrated that other immune
cells such as B cells, NK cells and effector T cells can also express
CXCR3 and mediates these cells mobilization [45,46]. The effect
of CXCL10 on other immune cells mobilization and their roles
in liver tumor recurrence after transplantation will be definitely
worthwhile for further studies.
In conclusion, we first defined the correlation among liver
graft injury, Tregs and late phase tumor recurrence after liver
transplantation. Post-transplant enhanced CXCL10/CXCR3 signal-
ing in acute-phase liver graft directly induced the mobilization
and recruitment of Tregs, which further promoted liver tumor
growth and recurrence after transplantation. Therefore, targeting
at CXCL10/CXCR3 signaling may attenuate acute-phase liver graft6 vol. 65 j 944–952
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JOURNAL OF HEPATOLOGYinjury induced Tregs mobilization and recruitment, and then pre-
vent late phase tumor recurrence.Financial support
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